The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 5, 2013, Pages 397-399

  Guedj, Jeremie ^a   Dahari, Harel ^b,c   Uprichard, Susan L ^b   Perelson, Alan S ^c  

^a INSERM   (France)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

daclatasvir; hepatitis C virus; multiscale model; NS5A inhibitor; viral kinetics

Indexed keywords

BOCEPREVIR; DACLATASVIR; INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ERADICATION THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE STAGE; NONHUMAN; PREDICTION; REVIEW; RNA DEGRADATION; RNA REPLICATION; SINGLE DRUG DOSE; TREATMENT DURATION; VIRAL CLEARANCE; VIRAL PHENOMENA AND FUNCTIONS; VIRION; VIRUS ASSEMBLY; VIRUS HALF LIFE; VIRUS LOAD;

EID: 84883253304     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.811050     Document Type: Review

References (17)

1. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 31(Suppl. 2), 1-3 (2011).
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006).
3. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon-2a is associated with higher sustained virological response than peginterferon-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 51(4), 1176-1184 (2010).
4. Chatterjee A, Guedj J, Perelson AS. Mathematical modelling of HCV infection: what can it teach us in the era of directacting antiviral agents Antivir. Ther. (Lond.) 17(6 Pt B), 1171-1182 (2012).
5. Guedj J, Dahari H, Rong L et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl Acad. Sci. USA 110(10), 3991-3996 (2013).
6. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465(7294), 96-100 (2010).
7. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-Alpha therapy. Science 282(5386), 103-107 (1998).
8. Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53(6), 1801-1808 (2011).
9. Rong L, Guedj J, Dahari H et al. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput. Biol. 9(3), e1002959 (2013).
10. Liang Y, Ishida H, Lenz O et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135(5), 1710.e2-1718.e2 (2008).
11. Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102(26), 9294-9299 (2005).
12. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005).
13. Sainz B Jr, Chisari FV. Production of infectious hepatitis C virus by welldifferentiated, growth-Arrested human hepatoma-derived cells. J. Virol. 80(20), 10253-10257 (2006).
14. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Trans. Med. 2(30), 30-32 (2010).
15. Pol S. Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment rationale and clinical trials. Clin. Investig. 3(2), 191-207 (2013).
16. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368(1), 34-44 (2013).
17. Guedj J, Pang PS, Lawitz E, Rodriguez-Torres M, Symonds B, Perelson AS. Analysis of the kinetics of viral decline during 14 days of administration of sofosbuvir and GS-0938. J. Hepat. 58(S1), S486-S487 (2013).